Core Viewpoint - Yidu Technology (02158) shares increased by over 5%, currently up 5.39% at HKD 6.06, with a trading volume of HKD 74.9734 million [1] Group 1: Company Developments - Yidu Technology announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately RMB 55.82 million [1] - The company positions itself as a driver of AI medical transformation in China, leveraging its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] Group 2: Industry Impact - Yidu Technology's innovations enable high-efficiency and low-cost scalable applications of AI technology, facilitating intelligent decision-making across the entire healthcare ecosystem, including "medicine-insurance-patients" [1]

Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 5%, currently trading at 6.06 HKD with a transaction volume of 74.9734 million HKD, following the announcement of a significant project win [1] Company Summary - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately 55.82 million RMB [1] - The company positions itself as a driver of AI transformation in healthcare, utilizing its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] - This system enables efficient innovation and low-cost scalable applications of AI technology, empowering intelligent decision-making across the entire healthcare ecosystem, including medicine, insurance, and patients [1]

Group 1 - The core point of the article is that Medu Technology announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., has won a bid for a Phase III clinical research project for the recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. [1] - The total amount of the project is approximately 55.82 million RMB [1]

作为中国AI医疗变革驱动者，医渡科技秉承"使精准医疗惠及每一个人"的使命，打造专业、高效、精准 且普惠的医学人工智能产品与解决方案。基于公司自主研发的核心算法引擎YiduCore，医渡科技构 建"数据-算法-场景"飞轮闭环，实现了AI技术的高效率创新、低成本规模化应用，推动智能决策赋 能"医-药-险-患者"全产业链生态。 AI医疗的核心是通过提升医学证据质量与生成效率，优化研发、诊断及治疗流程，最终实现更安全、 更优质、更可及的医疗服务。医渡科技持续提升医疗服务效率与可及性，让医生拥有更精准高效的决策 工具，让药企缩短分子到患者距离，让患者享有更可负担的精准诊断和治疗，让公共系统获得更科学的 支撑。医疗AI的价值，体现在对每一个个体生命的尊重与对健康福祉的守护。 医渡科技(02158)公布，近期，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限公 司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。 ...

Core Insights - Yidu Technology (02158) announced that its subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes to ultimately provide safer, higher-quality, and more accessible medical services [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, equipping doctors with precise and efficient decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and providing patients with affordable precision diagnosis and treatment [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

Core Viewpoint - Yidu Technology (02158) announced that its affiliate Tianjin Happy Life Technology Co., Ltd. won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.8176 million [1] Group 1 - Yidu Technology aims to drive AI medical transformation in China, adhering to the mission of making precision medicine accessible to everyone [1] - The company has developed a core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop, enabling efficient innovation and low-cost scalable applications of AI technology [1] - The value of medical AI is reflected in respecting individual lives and safeguarding health and well-being [1] Group 2 - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology continuously improves the efficiency and accessibility of medical services, providing doctors with precise decision-making tools and enabling pharmaceutical companies to shorten the distance from molecules to patients [1] - Patients benefit from more affordable precision diagnosis and treatment, while public systems receive more scientific support [1]

Core Insights - Yidu Technology announced that its subsidiary Tianjin Happy Life Technology Co., Ltd. won a bid for the Phase III clinical research project of the recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, providing doctors with precise decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and offering affordable precision diagnosis and treatment for patients [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

Core Viewpoint - Yidu Technology (医渡科技) has won a bid for a Phase III clinical research project for the recombinant human nerve growth factor (SMR001) eye drops, with a total project amount of approximately RMB 55,817,597.00 [1] Group 1: Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] Group 2: AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, providing doctors with precise decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and offering affordable precision diagnosis and treatment for patients [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

中標 重組人神經生長因子(SMR001)滴眼液III期臨床研究項目 醫渡科技有限公司（「本公司」，「醫渡科技」）欣然公佈，近期，本公司的聯屬公司天津開心生 活科技有限公司中標山東衍渡生物科技有限公司重組人神經生長因子(SMR001)滴眼液III期 臨床研究項目，項目總金額約為人民幣55,817,597.00元。 作為中國AI醫療變革驅動者，醫渡科技秉承「使精準醫療惠及每一個人」的使命，打造專業、 高效、精準且普惠的醫學人工智能產品與解決方案。基於公司自主研發的核心算法引擎 YiduCore，醫渡科技構建「數據 — 算法 — 場景」飛輪閉環，實現了AI技術的高效率創新、低 成本規模化應用，推動智能決策賦能「醫 — 藥 — 險 — 患者」全產業鏈生態。 Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) AI醫療的核心是通過提升醫學證據質量與生成效率，優化研發、診斷及治療流程，最終實現 更安全、更優質、更可及的醫療服務。醫渡科技持續提升醫療服務效率與可及性，讓醫生擁 有更精準高效的決策工具，讓藥企縮短分子到患者距離，讓患者享有更可 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 醫渡科技有限公司 | | | 呈交日期: | 2025年9月4日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 2,500,000,000 | USD | | 0.00002 USD ...